Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma | Zendy

Yoichi Yamashita | Zendy; Akinobu Taketomi | Zendy; Shinji Itoh | Zendy; Norifumi Harimoto | Zendy; Kazutoyo Morita | Zendy; Takasuke Fukuhara | Zendy; Shigeru Ueda | Zendy; Kensaku Sanefuji | Zendy; K Sugimachi | Zendy; Tsuyoshi Tajima | Zendy; Yoshihiko Maehara | Zendy

Open Access

Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma

Author(s) -

Yoichi Yamashita,

Akinobu Taketomi,

Shinji Itoh,

Norifumi Harimoto,

Kazutoyo Morita,

Takasuke Fukuhara,

Shigeru Ueda,

Kensaku Sanefuji,

K Sugimachi,

Tsuyoshi Tajima,

Yoshihiko Maehara

Publication year - 2009

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/s00280-009-1034-5

Subject(s) - hepatocellular carcinoma , medicine , cisplatin , carcinoma , phase (matter) , oncology , chemotherapy , chemistry , organic chemistry

Lipiodol Ultra-Fluid (Lipiodol(®)), an oily contrast medium, is selectively retained in hepatocellular carcinoma (HCC) through hepatic arterial infusion. DDP-H (IA-call(®)) developed as a CDDP powder, and may be a possible chemotherapeutic agent with lipiodol. We carried out a phase I/II study of the lipiodolization using DPP-H in patients with unresectable HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research